Cephalon’s Fentora sNDA Gets FDA Advisory Panel Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Company tells “The Pink Sheet” DAILY advisory committee meeting slated for May 6 is routine for schedule II opioids.
You may also be interested in...
Amrix And Treanda Take-up Bodes Well For Cephalon
New drugs help firm move on from fading Actiq, beset by generic erosion.
Amrix And Treanda Take-up Bodes Well For Cephalon
New drugs help firm move on from fading Actiq, beset by generic erosion.
Cephalon Submits Fentora sNDA For Chronic Pain
Application includes strengthened risk management plan to ensure appropriate patient use and dosing, a critical concern after deaths were reported following unapproved uses.